Katharine Yao to Receptor, ErbB-2
This is a "connection" page, showing publications Katharine Yao has written about Receptor, ErbB-2.
Connection Strength
1.218
-
Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx® for Hormone Receptor Positive Patients Undergoing Neoadjuvant Chemotherapy. Ann Surg Oncol. 2019 Oct; 26(10):3232-3239.
Score: 0.586
-
Molecular subtyping improves diagnostic stratification of patients with primary breast cancer into prognostically defined risk groups. Breast Cancer Res Treat. 2015 Nov; 154(1):81-8.
Score: 0.450
-
The Impact of Facility Volume on Rates of Pathologic Complete Response to Neoadjuvant Chemotherapy Used in Breast Cancer. Ann Surg Oncol. 2017 Oct; 24(11):3157-3166.
Score: 0.127
-
A Predictive Model for Axillary Node Pathologic Complete Response after Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg Oncol. 2018 May; 25(5):1304-1311.
Score: 0.033
-
Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients. Ann Surg Oncol. 2012 Oct; 19(10):3257-63.
Score: 0.023